Journal of Surgery Concepts & Practice ›› 2018, Vol. 23 ›› Issue (01): 52-56.doi: 10.16139/j.1007-9610.2018.01.012

• Original article • Previous Articles     Next Articles

Clinical importance of recurrent laryngeal nerve lymph nodes at entrance point in central lymph node dissection for papillary thyroid carcinoma

LÜ Tian1, WANG Lin2, YING Xiayang1, CHEN Xi1, DI Zhongmin1, KUANG Jie1, YAN Jiqi1   

  1. 1. Department of Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China;
    2. Department of General Surgery, Wujiang District Hospital of Integrated Traditional Chinese and Western Medicine, Jiangsu Suzhou 215000, China
  • Received:2017-07-19 Online:2018-01-25 Published:2020-07-25

Abstract: Objective To explore the clinical significance of metastasis to recurrent laryngeal nerve lymph nodes at entrance point (RLNLN-ep) in the patients with papillary thyroid carcinoma (PTC). Methods An analysis was done inclu-ding 598 consecutive patients with PTC who underwent thyroid surgery from April 2016 to November 2016. We explored RLNLN-ep in central compartment lymph node dissection. Carbon nanoparticles were injected into the lobes to help identify lymph nodes. RLNLN-ep and the other central compartment lymph nodes were sent for pathological examination. The complications were recorded. Results RLNLN-ep was found in 35 of 598 (5.85%) cases. There were 15 (2.51%) cases with metastasis of PTC and 20 cases without the metastasis. The metastasis rate of RLNLN-ep was related to tumor diameter, tumor location and the amount of tumor. The amount of tumor was an independent factor of metastasis of RLNLN-ep. There were 14 (93.3%) cases with metastasis of RLNLN-ep who were found the other central compartment lymph node metastasis simultaneously. Seven (1.2%) cases had morbidity postoperatively. Conclusions RLNLN-ep could be the site of metastasis of PTC. Central compartment lymph node dissection should include RLNLN-ep and the surrounding tissue.

Key words: Recurrent laryngeal nerve lymph nodes at entrance point, Papillary thyroid carcinoma, Central compartment lymph node dissection

CLC Number: